Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Diluted EPS of $0.19 per share (loss) for fiscal year 2025.
CUMBERLAND PHARMACEUTICALS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.19 | +58.7% |
| 2024 | -$0.46 | -4.5% |
| 2023 | -$0.44 | -15.8% |
| 2022 | -$0.38 | -58.3% |
| 2021 | -$0.24 | -9.1% |
| 2020 | -$0.22 | +4.3% |
| 2019 | -$0.23 | +48.9% |
| 2018 | -$0.45 | +10.0% |
| 2017 | -$0.50 | -733.3% |
| 2016 | -$0.06 | -250.0% |
| 2015 | $0.04 | -71.4% |
| 2014 | $0.14 | +227.3% |
| 2013 | -$0.11 | -136.7% |
| 2012 | $0.30 | +7.1% |
| 2011 | $0.28 | +133.3% |
| 2010 | $0.12 | -29.4% |
| 2009 | $0.17 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.13 | -18.2% | -160.0% |
| June 30, 2025 | -$0.05 | +37.5% | -162.5% |
| March 31, 2025 | $0.08 | +157.1% | +172.7% |
| September 30, 2024 | -$0.11 | -57.1% | -37.5% |
| June 30, 2024 | -$0.08 | -233.3% | +42.9% |
| March 31, 2024 | -$0.14 | -1500.0% | -100.0% |
| September 30, 2023 | -$0.07 | -133.3% | -216.7% |
| June 30, 2023 | $0.06 | +166.7% | +500.0% |
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +58.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2009–2025 period, CUMBERLAND PHARMACEUTICALS INC’s diluted eps has declined by 211.8% (from $0.17 per share to $0.19 per share (loss)).
- The most recent figure is from CUMBERLAND PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: